Şebnem ÇALIK, Alpay ARI, Ufuk SÖNMEZ, Reyhan YİŞ, Deniz Yüce YILDIRIM, Meltem ZENCİR, Selma TOSUN

EVALUATION OF CLINICAL CHARACTERISTICS AND MORTALITY OF KLEBSIELLA PNEUMONIAE BLOODSTREAM INFECTIONS IN A TEACHING HOSPITAL

Introduction: The aim of this study was to describe clinical characteristics of Klebsiella pneumoniae bloodstream infection (KPBSI) in patients admitted to a teaching hospital and to evaluate the risk factors related to overall patient mortality from those infections. Material and Method: This retrospective cohort study was conducted with hospitalized patients in a training and research hospital between 2012 and 2016. Data were recorded to the electronic patient data monitoring system. Result: A total of 288 patients with KPBSI were identified, and 155 (53.8%) male patients ranging from 18 to 104 (63.4±17.8) years old were included in the study. Most of the KPBSI (79.5%) were acquired in hospitals.

BİR EĞİTiM VE ARAŞTIRMA HASTANESİNDE KLEBSİELLA PNEUMONİAE KAN DOLAŞIMI ENFEKSİYONLARININ KLİNİK ÖZELLİKLERİ VE MORTALİTENİN DEĞERLENDİRİLMES

Giriş: Bu çalışmanın amacı bir eğitim ve araştırma hastanesine kabul edilmiş Klebsiella pneumoniae kan dolaşımı enfeksiyonu (KPKDE) gelişen hastaların klinik özelliklerini ve bu enfeksiyonlara bağlı genel hasta mortalitesi ile ilişkili risk faktörlerini değerlendirmektir. Gereç ve Yöntem: Bu retrospektif kohort çalışması bir eğitim ve araştırma hastanesinde 2012-2016 yılları arasında yatırılarak izlenmiş hastalarla yapılmıştır. Elektronik hasta izleme sistemindeki veriler kaydedilmiştir. Bulgular: Çalışmaya KPKDE gelişmiş toplam 288 hasta dahil edilmiştir ve yaşları 18-104 aralığında olan hastaların 155 (%53.8)’i erkektir. KPKDE'nin çoğu (% 79.5) hastane kaynaklıdır. İkiyüzseksensekiz KPKDE’nin 64'ü (% 22.2) karbapeneme dirençli K. pneumoniae'ye bağlı gelişmiştir. Karbapenem direnci gelişmesi için en önemli risk faktörü antibiyotik kullanımıdır. İkiyüzseksensekiz KPKDE’nin 28 günlük mortalite oranı % 49.6’dır. Yirmisekiz günlük KPKDE mortalitesi için en önemli risk faktörü ciddi sepsistir. Sonuç: Çalışmamızda KPKDE gelişen hastaların çoğunun hastane kaynaklı enfeksiyonlar olduğunu bulduk. Mortalite için en önemli risk faktörü ciddi sepsistir. Enfeksiyon hastalıkları uzmanları, KPKDE gelişen olgularda uygun ampirik tedavinin erken dönemde başlanmasını gözönünde bulundurmalıdır.

PDF

___

Tian L, Tan R, Chen Y, Sun J, Liu J, Qu H, Wang X. Epidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: Factors related to the carbapenem resistance and patient mortality. Antimicrob Resist Infect Control 2016; 5: 48.

Papadimitriou-Olivgeris M, Marangos M, Christofidou M, Fligou F, Bartzavali C, Panteli ES, et al. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit. Scand J Infect Dis 2014; 46(9): 642–8.

Durdu B, Hakyemez IN, Bolukcu S, Okay G, Gultepe B, Aslan T. Mortality markers in nosocomial Klebsiella pneumoniae bloodstream infection. Springerplus 2016; 5(1): 1892.

Aktaş Z, Kayacan CB, Schneider I, Can B, Midilli K, Bauernfeind A. Carbapenem- hydrolyzing oxacillinase, OXA-48, persists in Klebsiella pneumoniae in Istanbul, Turkey. Chemotherapy 2008; 54(2): 101–106.

Zarakolu P, Eser OK, Aladag E, Al-Zahrani IA, Day KM, Atmaca O, et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization: A surveillance study at a Turkish university hospital from 2009 to 2013. Diagn Microbiol Infect Dis 2016; 85(4): 466–70.

Pitout JD, Laupland KB. Extended-spectrum beta-lactamase producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect Dis 2008; 8(3): 159–66.

MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SG, Gould IM. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet 199;, 350(9080): 783.

Akgul F, Bozkurt I, Sunbul M, Esen S, Leblebicioglu H. Risk factors and mortality in the carbapenem-resistant Klebsiella pneumoniae infection: Case control study. Pathog Glob Health 2016; 10(7–8): 321–5.

Salman N. Carbapenem-resistant Klebsiella pneumoniae colonization in pediatric and neonatal intensive care units: Risk factors for progression to infection. Braz J Infect Dis 2016; 20(2): 134–40.

Karabay O, Altindis M, Koroglu M, Karatuna O, Aydemir ÖA, Erdem AF. The carbapenem-resistant Enterobacteriaceae threat is growing: NDM-1 epidemic at a training hospital in Turkey. Ann Clin Microbiol Antimicrob 2016; 15: 6.

Ulu-Kilic A, Alp E, Percin D, Cevahir F, Altay-Kürkçü C, Ozturk A, et al. Risk factors for carbapenem resistant Klebsiella pneumoniae rectal colonization in pediatric units. J Infect Dev Ctries 2014; 8(10): 1361–4.

Balkan II, Aygün G, Aydın S, Mutcalı SI, Kara Z, Kuşkucu M, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: Treatment. Int J Infect Dis 2014; 26: 51–6.

Us E, Tekeli A, AO, Dolapci I, Sahin F, Karahan ZC. Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae strains isolated between 2004-2007 in Ankara University Hospital, Turkey. Mikrobiyol Bul 2010; 44(1):1–10.

Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36(5): 309–32.

Surviving Sepsis Campaign. International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. http://www.sccm.org/Documents/SSC-Guidelines.pdf. Accessed 29 December 2018.

Clinical and Laboratory Standards Institute (2013) Performance Standards for Antimicrobial Susceptibility Testing, TwentyThird Informational Supplement. Accessed 29 December 2018.

Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: A multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014; 20(2): 117–123.

Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates A, Voutsinas D, et al. A. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: A matched case-control study. J Clin Microbiol 2010; 48(6): 2271–4.

Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012; 18(1): 54–60.

Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 2012; 55(7): 943–50.

Vardakas KZ, Matthaiou Dk, Falagas Me, Antypa E, Koteli A, Antoniadou E. Characteristics, risk factors and outcomes of carpanem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infect 2015; 70(6): 592–9.

van Duin D, Perez F, Rudin SD, Cober E, Hanrahan J, Ziegler J, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: Tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 2014; 58(7): 4035–41.

Kang CI, Kim SH, Bang JW, Kim HB, Kim NJ, Kim EC, et al. Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: Clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci 2006; 21(5): 816–22.

Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58(4): 2322–8.

Pau CK, Ma FF, Ip M, You JH. Characteristics and outcomes of Klebsiella pneumoniae bacteraemia in Hong Kong. Infect Dis (Lond) 2015; 47(5): 283–8.

Wu HS, Wang FD, Tseng CP, Wu TH, Lin YT, Fung CP. Characteristics of healthcare-associated and community-acquired Klebsiella pneumoniae bacteremia in Taiwan. J Infect 2012; 64(2): 162–8.

Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, et al. Risk factors of carbapenemresistant Klebsiella pneumoniae infections: A matched case control study. J Antimicrob Chemother 2007; 60: 1124–30.

Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: Risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009; 30: 666–71.

Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: Factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010; 67(2): 180–4.

Cristina ML, Alicino C, Sartini M, Faccio V, Spagnolo AM, Del Bono V, et al. Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area. J Infect Public Health 2018; 11(2):171-7.

Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I, et al. Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect 2013; 83(4):307–13.